Company intelligence / Profile preview
Direct Biologics
Austin, Texas, United Statesdirectbiologics.com ↗
- Ownership
- Private
- Development stage
- Phase 3
01
Overview
Currently conducting global Phase 3 EXTINGUISH ARDS clinical trial for ExoFlo in treating moderate-to-severe ARDS. Phase 1 trials initiated for ulcerative colitis and Crohn's disease. Expanded access trials in solid abdominal organ transplantation and severe ARDS patients. Planning Phase 1b/2a trial for perianal fistulizing Crohn's disease.
- Therapeutic areas
- GastroenterologyPulmonologyImmunology
- Modalities
- Extracellular Vesicles (EVs) from bone marrow mesenchymal stem/stromal cells
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on Direct Biologics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Direct Biologics.